Youngjin Da-Dueo Extended-Release Tablet 10/1000 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youngjin Pharmaceutical Co., Ltd.
MFDS item code 202300152 · Approved 2023.01.06
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, combining dapagliflozin and metformin. Special caution is required for patients with a history of cardiovascular disease or risk factors when blood sugar is not adequately controlled. Please refer to detailed clinical study information from professionals before administration. This medication effectively improves blood sugar control and is used in the treatment of type 2 diabetes.
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication is used in diabetes treatment and may cause a rare side effect known as severe lactic acidosis; therefore, caution is needed. It may be risky to use this medication in patients with impaired kidney function, acute illness, or dehydration. Additionally, when taken with other diabetes medications like insulin or sulfonylureas, there may be a risk of hypoglycemia, necessitating dosage adjustments. This medication should not be administered to patients with moderate to severe impairment of kidney function, and should be discontinued during certain periods before and after surgery. Women who are pregnant or breastfeeding should not take this medication, and patients with specific genetic disorders affecting lactose metabolism should also avoid it. During treatment, kidney function and fluid status should be regularly monitored, and immediate consultation with medical personnel is necessary if symptoms of hypotension or dehydration occur. During the use of this medication, genitourinary and urinary tract infections may occur, and timely treatment should be sought if related symptoms arise. Vitamin B12 deficiency may occur, so checking vitamin B12 levels is advisable for prolonged use. Excessive alcohol consumption may increase the risk of side effects from this medication; thus, it should be avoided. Particular caution should be taken when administering this medication to the elderly, regarding the risk of decreased kidney function and fluid loss, and dosage adjustments may be necessary. In case of overdose, seek immediate medical attention for appropriate treatment, and dialysis may be helpful if needed. Lastly, this medication is not recommended for use in children, as safety and efficacy have not been established. Caution should be exercised while driving or operating machinery, as dizziness may occur during the use of this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent degradation.
Yellow, double convex, oval-shaped extended-release film-coated tablet
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youngjin Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.